Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on March 7, 2017, reporting events occurring on March 1, 2017. The filing details the completion of a bridge financing agreement with three accredited investors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data. It reports the following specific financial obligations and capital raises:
- Loan Proceeds: $250,000 received in aggregate principal amount.
- Interest Rate: 6% per annum on the convertible promissory notes.
- Warrants Issued: 100,000 shares of common stock at an exercise price of $5.90 per share.
- Maturity Date: The earlier of the 5-year anniversary of issuance or the completion of a "Qualified Financing" (equity financing raising at least $2,000,000).
Material Changes
The primary material change is the entry into a definitive agreement creating a direct financial obligation. The company has increased its debt load by $250,000 and issued equity-linked warrants. No prior period financial comparisons are provided in this filing.
Guidance, Outlook, and Risks
Management Commentary and Terms:
- Conversion Mechanics: Upon maturity or a Qualified Financing, investors may convert debt to equity at a price equal to the lesser of 80% of the implied valuation or $5.90 per share.
- Change of Control: In the event of a change of control, investors may elect cash repayment or immediate conversion at a discounted valuation.
- Warrant Restrictions: Warrants are immediately exercisable but subject to a 9.99% beneficial ownership limitation unless adjusted with 61 days' notice.
- The company faces a liquidity milestone requirement to trigger early repayment or conversion via a Qualified Financing of at least $2,000,000.
- Dilution risk exists for existing shareholders due to the conversion discount (80% of valuation) and warrant exercise.
Investor Verification Checklist
- Verify the company's current cash position and ability to service the 6% interest or repay the $250,000 principal if a Qualified Financing is not achieved within 5 years.
- Confirm the status of any ongoing equity financing efforts to determine if the $2,000,000 Qualified Financing threshold is imminent.
- Review the full text of Exhibits 10.1 (Form of Note) and 10.2 (Form of Warrant) for specific anti-dilution adjustments and registration rights.
- Assess the potential dilution impact of the 100,000 warrant shares and the potential conversion of the $250,000 debt at the 80% discount rate.